Drugs / PEP-CMV
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06132438 | Nov 2023 → Sep 2024 overdue | glioblastoma | Charlotte Lemech | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03299309 | Jun 2018 → Apr 2023 overdue | brain cancer, malignant glioma, medulloblastoma | Daniel Landi | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06639607 | Aug 2026 → Aug 2031 | ependymoma, medulloblastoma | Washington University School of Medicine | Suspended | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05096481 | Jul 2024 → Jun 2028 expected | diffuse intrinsic pontine glioma, high grade astrocytic tumor, medulloblastoma | Nationwide Children's Hospital | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01854099 Comparator | Jan 2014 | glioblastoma | University of Florida | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEP-CMV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06132438 ↗ |
| Known as | PEP-CMV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06639607 ↗ |
| Modality | Vaccine | “PEP-CMV vaccine” NCT01854099 ↗ |
| Route | Other | “intradermally administered half in the RIGHT groin and half in the LEFT groin.” NCT05096481 ↗ |